Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.

Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.

Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.

Abstract: The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.

Abstract: The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.

Abstract: The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.

Abstract: The invention relates to new nucleic acid sequences of the family of tumour-suppressing genes related to the gene for the p53 protein, and to the corresponding protein sequences.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.

Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.

Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and/or IL13 receptor ? and uses thereof.

Abstract: This invention relates to a purified polypeptide, comprising an amino acid sequence chosen from: a) the sequence SEQ ID No. 2, b) any biologically active sequence derived from SEQ ID No. 2.

Abstract: The invention relates to new nucleic acid sequences of the family of tumour-suppressing genes related to the gene for the p53 protein, and to the corresponding protein sequences.

Abstract: This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.

Abstract: This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.

Abstract: A new chemotactic cytokine, NC28 or Monocyte Chemotactic Protein-3 (MCP-3), is provided. Fragments of the cytokine comprising its 13 C-terminal amino acids also exhibit chemotactic activity. The polypeptides may be used as anticancer agents or immunomodulators. DNA encoding the NC28/MCP-3 polypeptides, as well as corresponding vectors and recombinant expression systems, are also provided.

Abstract: The subject of the present invention is a protein having cytokine type activity, or a precursor of this protein, which comprises the following amino acid sequence (a1): ##STR1## in which Xaa represents Asp or Gly.

Abstract: The invention concerns a new urate oxidase activity protein which has the following sequence (SEQ ID NO:1): ##STR1## optionally preceded by a methionine, or in that it may present a degree of substantial homology with this sequence.The invention is also aimed at medicines containing this protein as well as the genetic engineering implements to obtain it.

Abstract: The invention concerns a new urate oxidase activity protein which has the following sequence:______________________________________ Ser Ala Val Lys Ala Ala Arg Tyr Gly Lys Asp Asn Val Arg Val Tyr Lys Val His Lys Asp Glu Lys Thr Gly Val Gln Thr Val Tyr Glu Met Thr Val Cys Val Leu Leu Glu Gly Glu Ile Glu Thr Ser Tyr Thr Lys Ala Asp Asn Ser Val Ile Val Ala Thr Asp Ser Ile Lys Asn Thr Ile Tyr Ile Thr Ala Lys Gln Asn Pro Val Thr Pro Pro Glu Leu Phe Gly Ser Ile Leu Gly Thr His Phe Ile Glu Lys Tyr Asn His Ile His Ala Ala His Val Asn Ile Val Cys His Arg Trp Thr Arg Met Asp Ile Asp Gly Lys Pro His Pro His Ser Phe Ile Arg Asp Ser Glu Glu Lys Arg Asn Val Gln Val Asp Val Val Glu Gly Lys Gly Ile Asp Ile Lys Ser Ser Leu Ser Gly Leu Thr Val Leu Lys Ser Thr Asn Ser Gln Phe Trp Gly Phe Leu Arg Asp Glu Tyr Thr Thr Leu Lys Glu Thr Trp Asp Arg Ile Leu Ser Thr Asp Val Asp Ala Thr Trp Gln Trp Lys Asn Phe Ser Gly Leu Gln Glu Val Arg Ser His Val Pro Lys Phe Asp Ala Thr Trp Ala Thr Ala Arg Glu Val Thr Leu Lys Thr Phe Ala Glu Asp Asn

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host.The bacteriophage .lambda.FVIII23D containing the 14.43kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on July 17, 1985 and given Accession No. 40190.